<DOC>
	<DOCNO>NCT00707382</DOCNO>
	<brief_summary>The purpose study determine whether genotyping CYP2D6 2C19 polymorphism intense clinical monitoring treatment adverse effect improve antipsychotic treatment patient schizophrenia . This study design three-armed prospective randomize control clinical trial include 300 patient schizophrenia . Patients follow period one year . During study period follow effect measure register : - Time discontinuation antipsychotic medication - Number change medication dose - Number change medication - Compliance ( patientsÂ´ adherence medical treatment ) - Clinical symptom - Adverse effect</brief_summary>
	<brief_title>Effect Genotyping CYP450 Polymorphisms Versus Intense Clinical Monitoring Antipsychotic Drug Treatment</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<criteria>Diagnosed schizophrenia Able give write informed consent Genotyped prior inclusion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Pharmacogenetics</keyword>
	<keyword>Compliance</keyword>
	<keyword>Antipsychotic drug</keyword>
	<keyword>Schizophrenia</keyword>
</DOC>